Compare Neurocrine Biosciences Inc (NBIX) vs Synchrony Financial (SYF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Synchrony Financial — how do they compare? Neurocrine Biosciences Inc trades at $155.5 (market cap $15.77B), while Synchrony Financial trades at $77.5 (market cap $25.17B). The key difference: Synchrony Financial is the larger of the two by market cap, and Synchrony Financial pays a 1.76% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | SYF | |
|---|---|---|
Market Cap | $15.77B | $25.17B |
Sector | Health | Financials |
52-Week High | $185.50 | $88.47 |
52-Week Low | $123.10 | $63.78 |
Enterprise Value | $15.78B | — |
Dividend Yield | — | 1.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
Synchrony Financial (SYF) trades at $78.62, down 1.63% on the day, with a neutral technical signal. The stock shows strong fundamentals with a low P/E of 8.06 and robust profitability, including a 23.4% net income margin and 22.23% ROE. Recent earnings beats and a strategic partnership with OpenAI for AI-driven commerce highlight growth initiatives. Analyst consensus is bullish with a $87.33 price target and no sell ratings.
The outlook remains positive given valuation appeal, consistent earnings performance, and AI partnership potential. Key risks include consumer credit deterioration amid economic uncertainty and increased investing cash outflows. Institutional ownership trends and strong buyback activity support the bullish case, but credit quality monitoring is essential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Synchrony Financial
Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →
